MUS81 Inhibition Enhances the Anticancer Efficacy of Talazoparib by Impairing ATR/CHK1 Signaling Pathway in Gastric Cancer

Tao Wang(Union Hospital), Yuping Yin(Wuhan Union Hospital)

Frontiers in Oncology

April 11, 2022

10.3389/fonc.2022.844135

Cited by 9

Related Papers

Combination of <scp>PARP</scp> inhibitor and <scp>CDK4</scp>/6 inhibitor modulates <scp>cGAS</scp>/<scp>STING‐</scp>dependent therapy‐induced senescence and provides “one‐two punch” opportunity with <scp>anti‐PD‐L1</scp> therapy in colorectal cancer

|Cancer Science|2023|38

Cell Cycle Regulation of DNA Polymerase Beta in Rotenone-Based Parkinson's Disease Models

|PLoS ONE|2014|17

Two-Year Outcomes and Biomarker Analysis of Locally Advanced Gastric and Gastroesophageal Junction Adenocarcinoma After Neoadjuvant Chemotherapy and Immunotherapy from the Phase II WuhanUHGI001 Trial

|Annals of Surgical Oncology|2024|14

A prognostic model based on the Augmin family genes for LGG patients

|Scientific Reports|2023|8

Preoperative serum magnesium level as a prognostic and predictive biomarker in locally advanced gastric cancer patients receiving neoadjuvant immunochemotherapy

|World Journal of Surgical Oncology|2025|2